RecruitingPhase 3NCT05232279

Effect of Testofen on Erectile Function in an Adult Male Population

Effect of Testofen on Erectile Function in an Adult Male Population - A Double Blind, Randomised Controlled Trial.


Sponsor

RDC Clinical Pty Ltd

Enrollment

120 participants

Start Date

Apr 19, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

This is a double blind, randomised, placebo-controlled clinical study with a 12-week participation and 3 groups (2 active groups and 1 placebo group) designed to monitor erectile function symptom severity and the effect Testofen may have on improving erectile function, sexual function, and quality of life.


Eligibility

Sex: MALEMin Age: 40 YearsMax Age: 75 Years

Inclusion Criteria7

  • Healthy male adults aged 40-75 years
  • Currently in a sexual relationship
  • Males with reduced erectile function (Score of <25 on IIEF)
  • BMI ≤ 35
  • Able to provide informed consent
  • Agree not to change current diet and exercise program while enrolled in this trial
  • Agree not to undertake another clinical trial while enrolled in this trial

Exclusion Criteria14

  • History of prostate surgery and/or trauma
  • Receiving/prescribed treatment for erectile dysfunction, including oral medications, vacuum devices, constrictive devices, injections, or urethral suppositories
  • Receiving/prescribed treatment to increase/decrease testosterone levels e.g. androgens/anti androgens
  • Receiving/prescribed treatment to increase/decrease nitrate or nitric oxide levels
  • Unstable or serious illness (e.g. serious mood disorders, neurological disorders such as MS, kidney disease, liver disease, heart conditions, diabetes, hormone production disorders)*
  • All current malignancies (excluding BCC) or chemotherapy and/or radiotherapy treatment for malignancy within the previous 2 years
  • Receiving/prescribed \[e.g., Coumadin or Marevan (warfarin), heparin, dalteparin, enoxaparin) or other anticoagulation therapy (e.g., thromboembolectomy or the use of vena cava filters)
  • Active smokers, nicotine use, alcohol, or drug (prescription or illegal substances) abuse
  • Chronic past and/or current alcohol use (>14 alcoholic drinks week)
  • Allergic to any of the ingredients in the active or placebo formula
  • Any condition which in the opinion of the investigator makes the participant unsuitable for inclusion
  • Participants who have participated in any other related clinical study during the past 1 month
  • a Any participant reporting having been told by their doctor that they have an under or over production of hormones (e.g., testosterone).
  • *An unstable illness is any illness that is currently not being treated with a stable dose of medication or is fluctuating in severity. A serious illness is a condition that carries a risk of mortality, negatively impacts quality of life and daily function and/or is burdensome in symptoms and/or treatments.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTestofen 300mg

Testofen in capsule form - To be taken as a 300mg dosage (2 capsules) once daily for 12 weeks.

DRUGTestofen 600mg

Testofen in capsule form - To be taken as a 600mg dosage (2 capsules) once daily for 12 weeks.

DRUGPlacebo comparator

The placebo will consist of maltodextrin and will appear identical to the Testofen capsules. The placebo will be administered as per the active treatment - 2 capsules once daily for 12 weeks.


Locations(1)

RDC Clinical Pty Ltd

Brisbane, Queensland, Australia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05232279


Related Trials